BACKGROUND: Recent mathematical models suggested that frequent human immunodeficiency virus (HIV) testing with immediate initiation of antiretroviral therapy (ART) to individuals with a positive test result could profoundly curb transmission. The debate about ART as prevention has focused largely on parameter values. We aimed to evaluate structural assumptions regarding linkage to care and population mobility, which have received less attention. METHODS: We modified the linkage structure of published models of ART as prevention, such that individuals who decline initial testing or treatment do not link to care until late-stage HIV infection. We then added population mobility to the models. We populated the models with demographic, clinical, immigration, emigration, and linkage data from a South African township. RESULTS: In the refined linkage model, elimination of HIV transmission (defined as an incidence of <0.1%) did not occur by 30 years, even with optimistic assumptions about the linkage rate. Across a wide range of estimates, models were more sensitive to structural assumptions about linkage than to parameter values. Incorporating population mobility further attenuated the reduction in incidence conferred by ART as prevention. CONCLUSIONS: Linkage to care and population mobility are critical features of ART-as-prevention models. Clinical trials should incorporate relevant data on linkage to care and migration to evaluate the impact of this strategy.
BACKGROUND: Recent mathematical models suggested that frequent human immunodeficiency virus (HIV) testing with immediate initiation of antiretroviral therapy (ART) to individuals with a positive test result could profoundly curb transmission. The debate about ART as prevention has focused largely on parameter values. We aimed to evaluate structural assumptions regarding linkage to care and population mobility, which have received less attention. METHODS: We modified the linkage structure of published models of ART as prevention, such that individuals who decline initial testing or treatment do not link to care until late-stage HIV infection. We then added population mobility to the models. We populated the models with demographic, clinical, immigration, emigration, and linkage data from a South African township. RESULTS: In the refined linkage model, elimination of HIV transmission (defined as an incidence of <0.1%) did not occur by 30 years, even with optimistic assumptions about the linkage rate. Across a wide range of estimates, models were more sensitive to structural assumptions about linkage than to parameter values. Incorporating population mobility further attenuated the reduction in incidence conferred by ART as prevention. CONCLUSIONS: Linkage to care and population mobility are critical features of ART-as-prevention models. Clinical trials should incorporate relevant data on linkage to care and migration to evaluate the impact of this strategy.
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Maria Velasco; Virgilio Castilla; José Sanz; Gabriel Gaspar; Emilia Condes; Carlos Barros; Miguel Cervero; Rafael Torres; Carlos Guijarro Journal: J Acquir Immune Defic Syndr Date: 2009-02-01 Impact factor: 3.731
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Carol S Camlin; Adam Akullian; Torsten B Neilands; Monica Getahun; Anna Bershteyn; Sarah Ssali; Elvin Geng; Monica Gandhi; Craig R Cohen; Irene Maeri; Patrick Eyul; Maya L Petersen; Diane V Havlir; Moses R Kamya; Elizabeth A Bukusi; Edwin D Charlebois Journal: Health Place Date: 2019-05-29 Impact factor: 4.078
Authors: Barbara S Taylor; Emily Reyes; Elizabeth A Levine; Shah Z Khan; L Sergio Garduño; Yeycy Donastorg; Scott M Hammer; Karen Brudney; Jennifer S Hirsch Journal: AIDS Patient Care STDS Date: 2014-05-19 Impact factor: 5.078
Authors: Yamilé Molina; Angela Ulrich; Anna C Greer; Angela Primbas; Grace Wandell; Hugo Sanchez; Carolyn Bain; Kelika A Konda; Jesse L Clark; Robert De la Grecca; Manuel V Villarán; Siavash Pasalar; Javier R Lama; Ann C Duerr Journal: AIDS Care Date: 2019-01-07
Authors: Hamish McManus; Kathy Petoumenos; Katherine Brown; David Baker; Darren Russell; Tim Read; Don Smith; Lynne Wray; Michelle Giles; Jennifer Hoy; Andrew Carr; Matthew G Law Journal: Antivir Ther Date: 2014-11-07
Authors: Mohammad R Haider; Monique J Brown; Sabrina Karim; Khairul A Siddiqi; Bankole Olatosi; Xiaoming Li Journal: Int J STD AIDS Date: 2020-04-11 Impact factor: 1.359